Conjunctival Diseases

09/01/2014 - "[Guidelines for the clinical management of allergic conjunctival disease (2nd edition): the point of the management with using eye drops]."
06/01/2011 - "[Therapeutic approach for severe allergic conjunctival diseases--emergence of immunosuppressant eye drops]."
03/01/2014 - "Our findings suggest that rebamipide eyedrops might attenuate giant papillae in patients with allergic conjunctival diseases and that these eyedrops may be useful for the treatment of not only dry eye but also of allergic conjunctival diseases."
03/01/2014 - "Four patients with allergic conjunctival diseases with giant papillae (VKC or AKC) instilled rebamipide eyedrops three or four times a day for varying periods. "
09/01/2004 - "To investigate the induction of acute asthmatic attacks caused by several kinds of antiallergic eyedrops for the treatment of allergic conjunctival diseases in a patient with bronchial asthma and aspirin sensitivity. "

05/01/2012 - "To evaluate the efficacy of subjective symptoms, objective findings, and of a total tear IgE test kit in the diagnosis of allergic conjunctival diseases (ACD). "
05/01/2012 - "[Evaluation of the efficacy of subjective symptoms, objective findings, and of a total tear IgE detection kit in diagnosis of allergic conjunctival diseases]."
09/01/1993 - "Both IgE-mediated and non-IgE-mediated mechanisms may cause an immediate reaction as well as allergic inflammation, and nonspecific hyperreactivity may occur both as a result of allergic inflammation and as an independent mechanism in nonallergic conjunctival disease."
10/01/2003 - "[Clinical evaluation of measurement method for antigen specific IgE in tears of patients with allergic conjunctival disease]."
01/01/2001 - "Histamine release test and measurement of antigen-specific IgE antibody in the diagnosis of allergic conjunctival diseases."

01/01/1992 - "Our current conclusions are that (1) immune reactions are efficiently inhibited with constantly effective blood levels of cyclosporin A, which has enormously increased the rate of keratoplasty successful in these patients; (2) if drug blood levels fall too low due to noncompliance of the patient or to metabolic disturbances, immune reactions may occur, especially during the early postoperative months; (3) serious chronic surface problems, which are especially associated with chemical burns, atopic inflammation, and other chronic kerato-conjunctival diseases, are partly ameliorated but not completely eliminated (surface disorders are presently ranked as the number one cause of transplant failure, whereas immune reactions can be effectively suppressed by cyclosporin A); and (4) close medical follow-up has revealed no serious systemic complication of cyclosporin A prophylaxis over periods of up to 37 months. "

03/01/2014 - "Our findings suggest that rebamipide eyedrops might attenuate giant papillae in patients with allergic conjunctival diseases and that these eyedrops may be useful for the treatment of not only dry eye but also of allergic conjunctival diseases."
03/01/2014 - "Four patients with allergic conjunctival diseases with giant papillae (VKC or AKC) instilled rebamipide eyedrops three or four times a day for varying periods. "

11/01/2004 - "Further detailed studies investigating the roles of cytokines in the conjunctiva will elucidate the developing mechanism of allergic conjunctival diseases. "
11/01/2004 - "Therefore, we investigated the involvement of cytokines, which are produced by immunocompetent cells and conjunctival cells, in the infiltration of inflammatory cells into the conjunctiva, using an animal model for allergic conjunctival diseases (experimental immune-mediated blepharoconjunctivitis, EC). "
11/01/2004 - "[Roles of cytokines in the development of severe allergic conjunctival diseases: analyses using animal models]."
11/01/1985 - "The immunomodulating properties of these cytokines make an important in vivo role in the pathogenesis of inflammatory corneal and conjunctival diseases probable."

02/01/1988 - "Monoclonal antibodies were used for the study of inflammatory cellular subtypes, Langerhans' cells, and major histocompatibility complex class II antigens on the epibulbar conjunctiva obtained from individuals ranging in age from fetus to the seventh decade to compile basic data for comparison with other inflammatory and proliferative conjunctival diseases. "
03/01/1998 - "Conjunctival biopsy specimens obtained from patients with subacute (n = 8) or chronic conjunctival disease (n = 13) were analysed histologically and immunohistochemically using antibodies directed against EG1 (stored and secreted ECP), EG2 (secreted ECP), MBP, CD45 (common leucocyte antigen), CD3 (pan T cell marker), and HLA-DR (class II antigen). "

11/01/2013 - "In our clinical trials, the percentage of blood vessel coverage of ROIs was significantly higher in the images of hyperemia caused by allergic conjunctival diseases and hyperemia induced by Bimatoprost, compared with those of healthy volunteers. "
01/01/2012 - "Percentage blood vessel coverage increased in images of bimatoprost-induced hyperemia and hyperemia in allergic conjunctival diseases compared to the data from healthy volunteers. "
01/01/2012 - "We also used this software to evaluate bimatoprost-induced hyperemia and hyperemia in allergic conjunctival diseases. "

04/01/1977 - "A new technique is presented using impression of the conjunctiva with a plastic device to study the conjunctival response in various conjunctival disease states. "

02/01/1988 - "Monoclonal antibodies were used for the study of inflammatory cellular subtypes, Langerhans' cells, and major histocompatibility complex class II antigens on the epibulbar conjunctiva obtained from individuals ranging in age from fetus to the seventh decade to compile basic data for comparison with other inflammatory and proliferative conjunctival diseases. "

09/01/2007 - "To investigate the variations in total secretory IgA (sIgA) and house dust mite (HDM)-specific sIgA antibodies in tears of patients with allergic conjunctival disease (ACD). "
08/01/2000 - "To determine the correlation between serum levels of circulating autoantibody and the patients' conjunctival disease activity, the titer of anti-beta 4 antibodies was determined at monthly intervals during the course of IVIg therapy. "
10/01/2003 - "The method for determining antigen specific IgE antibodies in tears is clinically useful to diagnose and to investigate pathophysiology of allergic conjunctival diseases."
10/01/2003 - "Antigen specific IgE antibodies to Japanese cedar pollen or Housedust-Mites in tears of patients with allergic conjunctival diseases were examined. "
03/01/1998 - "Conjunctival biopsy specimens obtained from patients with subacute (n = 8) or chronic conjunctival disease (n = 13) were analysed histologically and immunohistochemically using antibodies directed against EG1 (stored and secreted ECP), EG2 (secreted ECP), MBP, CD45 (common leucocyte antigen), CD3 (pan T cell marker), and HLA-DR (class II antigen). "

01/01/1992 - "Our current conclusions are that (1) immune reactions are efficiently inhibited with constantly effective blood levels of cyclosporin A, which has enormously increased the rate of keratoplasty successful in these patients; (2) if drug blood levels fall too low due to noncompliance of the patient or to metabolic disturbances, immune reactions may occur, especially during the early postoperative months; (3) serious chronic surface problems, which are especially associated with chemical burns, atopic inflammation, and other chronic kerato-conjunctival diseases, are partly ameliorated but not completely eliminated (surface disorders are presently ranked as the number one cause of transplant failure, whereas immune reactions can be effectively suppressed by cyclosporin A); and (4) close medical follow-up has revealed no serious systemic complication of cyclosporin A prophylaxis over periods of up to 37 months. "

01/01/1992 - "Our current conclusions are that (1) immune reactions are efficiently inhibited with constantly effective blood levels of cyclosporin A, which has enormously increased the rate of keratoplasty successful in these patients; (2) if drug blood levels fall too low due to noncompliance of the patient or to metabolic disturbances, immune reactions may occur, especially during the early postoperative months; (3) serious chronic surface problems, which are especially associated with chemical burns, atopic inflammation, and other chronic kerato-conjunctival diseases, are partly ameliorated but not completely eliminated (surface disorders are presently ranked as the number one cause of transplant failure, whereas immune reactions can be effectively suppressed by cyclosporin A); and (4) close medical follow-up has revealed no serious systemic complication of cyclosporin A prophylaxis over periods of up to 37 months. "

01/01/2013 - "To evaluate the effectiveness of amniotic membrane transplantation (AMT) in management of corneal and conjunctival diseases in large clinical series. "
08/01/2004 - "These include the use of both autogenous and cadaveric acellular dermis in the management of lower eyelid retraction, and amniotic membrane transplantation in the management of tarsal conjunctival disease. "
01/01/1996 - "Indications for epithelial transplantation are as follows: For patients with unilateral cicatrizing conjunctival disease, the first option should be CAU. "

10/01/1994 - "All patients had quiescent disease at the time of the cryotherapy and no patients showed increased conjunctival disease activity after treatment. "
05/01/1975 - "Five weeks after treatment, the intensity of conjunctival disease in the tetracycline and rifampicin groups was reduced significantly when compared with boric acid, but at 19 weeks this suppression was found only in the tetracycline group. "

10/01/1994 - "All patients had quiescent disease at the time of the cryotherapy and no patients showed increased conjunctival disease activity after treatment. "